The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
The role of histone deacetylases (HDACs) in human cancer
Open accessAbstract
The balance of histone acetylation and deacetylation is an epigenetic layer with a critical role in the regulation of gene expression. Histone acetylation induced by histone acetyl transferases (HATs) is associated with gene transcription, while histone hypoacetylation induced by histone deacetylase (HDAC) activity is associated with gene silencing. Altered expression and mutations of genes that encode HDACs have been linked to tumor development since they both induce the aberrant transcription of key genes regulating important cellular functions such as cell proliferation, cell‐cycle regulation and apoptosis. Thus, HDACs are among the most promising therapeutic targets for cancer treatment, and they have inspired researchers to study and develop HDAC inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Bai, S., Ghoshal, K., Datta, J., Majumder, S., Yoon, S. O., & Jacob, S. T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.2.751-766.2005 · Cited by 109
RetractedNan, X., Ng, H.-H., Johnson, C. A., Laherty, C. D., Turner, B. M., Eisenman, R. N., & Bird, A. (1998) · Nature · doi:10.1038/30764 · Cited by 3,440
Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase
Yeung, F., Hoberg, J. E., Ramsey, C. S., Keller, M. D., Jones, D. R., Frye, R. A., & Mayo, M. W. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600244 · Cited by 2,750 · cited 3×
“In particular, the most prominent family member, SIRT1, regulates histone acetylation levels (mainly K16-H4 and K9-H3 positions) (Vaquero et al., 2004; Pruitt et al., 2006), and the acetylation of transcription factors such as p53 (Vaziri et al., 2001), p300 histone acethyltransferase (Bouras et al., 2005), E2F1 (Wang…”
BackgroundMethylated DNA and MeCP2 recruit histone deacetylase to repress transcription
Jones, P. L., Veenstra, G. J. C., Wade, P. A., Vermaak, D., Kass, S. U., Landsberger, N., Strouboulis, J., & Wolffe, A. P. (1998) · Nature Genetics · doi:10.1038/561 · Cited by 2,730
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
The coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase
Cohen, H. Y., Miller, C., Bitterman, K. J., Wall, N. R., Hekking, B., Kessler, B., Howitz, K. T., Gorospe, M., de Cabo, R., & Sinclair, D. A. (2004) · Science · doi:10.1126/science.1099196 · Cited by 1,924
Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,923
Self-citationHistone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Cited by
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Establishing neural crest identity: a gene regulatory recipe
Simões-Costa, M., & Bronner, M. E. (2015) · Development · doi:10.1242/dev.105445 · Cited by 649
Pro- and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells
Li, M., van Esch, B. C. A. M., Wagenaar, G. T. M., Garssen, J., Folkerts, G., & Henricks, P. A. J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.05.003 · Cited by 614
Epigenetic modifications of histones in cancer
Zhao, Z., & Shilatifard, A. (2019) · Genome Biology · doi:10.1186/s13059-019-1870-5 · Cited by 552
Glioma epigenetics: From subclassification to novel treatment options
Gusyatiner, O., & Hegi, M. E. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.010 · Cited by 541
Anti-cancer chalcones: Structural and molecular target perspectives
Mahapatra, D. K., Bharti, S. K., & Asati, V. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.05.004 · Cited by 495
Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Singh, N., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 398
Role of microbiota-derived short-chain fatty acids in cancer development and prevention
Mirzaei, R., Afaghi, A., Babakhani, S., Sohrabi, M. R., Hosseini-Fard, S. R., Babolhavaeji, K., Khani Ali Akbari, S., Yousefimashouf, R., & Karampoor, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111619 · Cited by 394
Microbial metabolite butyrate facilitates M2 macrophage polarization and function
Ji, J., Shu, D., Zheng, M., Wang, J., Luo, C., Wang, Y., Guo, F., Zou, X., Lv, X., Li, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep24838 · Cited by 334
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
Panobinostat for the Treatment of Multiple Myeloma
Laubach, J. P., Moreau, P., San-Miguel, J. F., & Richardson, P. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0530 · Cited by 255
Identification of cancer driver genes based on nucleotide context
Dietlein, F., Weghorn, D., Taylor-Weiner, A., Richters, A., Reardon, B., Liu, D., Lander, E. S., Van Allen, E. M., & Sunyaev, S. R. (2020) · Nature Genetics · doi:10.1038/s41588-019-0572-y · Cited by 255
Moreno, D. A., Scrideli, C. A., Cortez, M. A. A., De Paula Queiroz, R., Valera, E. T., Da Silva Silveira, V., Yunes, J. A., Brandalise, S. R., & Tone, L. G. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08301.x · Cited by 208
Chango, A., & Pogribny, I. (2015) · Nutrients · doi:10.3390/nu7042748 · Cited by 144
“In contrast, histone lysine deacetylation, catalyzed by several different classes of histone deacetylases (HDACs), is associated with gene silencing [27].”
BackgroundTargeted protein acetylation in cells using heterobifunctional molecules
Wang, W. W., Chen, L.-Y., Wozniak, J. M., Jadhav, A. M., Anderson, H., Malone, T. E., & Parker, C. G. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c07850 · Cited by 114
Targeting the acetylation signaling pathway in cancer therapy
Dang, F., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.001 · Cited by 109
MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer
Noh, J. H., Chang, Y. G., Kim, M. G., Jung, K. H., Kim, J. K., Bae, H. J., Eun, J. W., Shen, Q., Kim, S.-J., Kwon, S. H., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.03.003 · Cited by 102
HDAC inhibitors: A new promising drug class in anti-aging research
Pasyukova, E. G., & Vaiserman, A. M. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.08.008 · Cited by 99
Mathias, R. A., Guise, A. J., & Cristea, I. M. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o114.046565 · Cited by 93
The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs
Geurs, S., Clarisse, D., De Bosscher, K., & D’hooghe, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00226 · Cited by 58
Liu, T.-I., Lu, T.-Y., Yang, Y.-C., Chang, S.-H., Chen, H.-H., Lu, I.-L., Sabu, A., & Chiu, H.-C. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120229 · Cited by 50
Inhibition of histone deacetylases in melanoma—a perspective from bench to bedside
Hornig, E., Heppt, M. V., Graf, S. A., Ruzicka, T., & Berking, C. (2016) · Experimental Dermatology · doi:10.1111/exd.13089 · Cited by 50
Mostofa, A., Distler, A., Meads, M. B., Sahakian, E., Powers, J. J., Achille, A., Noyes, D., Wright, G., Fang, B., Izumi, V., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151713 · Cited by 27
Dai, Y., Wei, T., Huang, Y., Bei, Y., Lin, H., Shen, Z., Yu, L., Yang, M., Xu, H., He, W., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04945-y · Cited by 22
HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia
Mehdipour, P., Santoro, F., Botrugno, O. A., Romanenghi, M., Pagliuca, C., Matthews, G. M., Johnstone, R. W., & Minucci, S. (2017) · Leukemia · doi:10.1038/leu.2017.3 · Cited by 25
Chattree, V., Singh, K., Singh, K., Goel, A., Maity, A., & Lone, A. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14259 · Cited by 19
Metadata
- Authors
- Ropero, S., & Esteller, M.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2007-03-07
- Volume
- 1
- Issue
- 1
- Pages
- 19-25
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2165638033
- Cited by
- 997
- References
- 62
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.